DexCom, Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy and hold forever. On September 22, UBS reiterated a ‘Buy’ rating on the stock and a $106 price target. The research firm reiterated ...

In other recent news, DexCom has been the focus of various analyst reports and market reactions regarding its G7 continuous glucose monitoring device. UBS maintained its Buy rating for DexCom, setting ...

Investing.com -- DexCom (NASDAQ:DXCM) stock fell 3% Thursday after Hunterbrook Media published a scathing short report alleging serious safety issues with the company’s G7 continuous glucose ...

LONDON--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM ...

Dexcom, maker of continuous glucose monitors (CGMs) this week announced a voluntary recall of all lots and models of its G4 Platinum and G5 Mobile receivers. The audio alert on some of the receivers ...